CanariaBio Inc. is a Korean biopharmaceutical
company focused on the development and
commercialization of immunotherapies for cancer.

Our mission is to save lives by bringing innovative therapeutics to patients who have limited treatment options. We are focused on developing immunotherapy for cancers with high unmet medical needs. Our lead product oregovomab is a first-in-class immunotherapy for ovarian cancer, which has the highest fatality rate among cancers affecting women. The second pipeline, AR20.5, targets pancreatic cancer, which accounts for 7% of all cancer deaths.

We will accomplish our mission through experienced leadership, a commitment to excellence,

On behalf of CanariaBio team, I thank you for you continue support of our company.